The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Open accessAbstract
Summary Background The Wee1 inhibitor adavosertib (AZD1775/MK1775) and gemcitabine demonstrated preclinical synergy and promising activity in early-phase clinical trials. Methods Women with measurable recurrent platinum-resistant/-refractory high-grade serous ovarian cancer were randomised 2:1 to receive intravenous gemcitabine (1000 mg/m2 on days 1, 8, and 15) with either oral adavosertib (175 mg) or placebo (once daily on days 1, 2, 8, 9, 15, and 16) every 28 days until progression or unacceptable toxicity. The primary endpoint was progression-free survival. Potential predictive factors were analysed using archival tissue (TP53 mutations by Sanger sequencing and immunohistochemistry) and paired tumour biopsies (by whole-exome and RNA sequencing). The trial is registered with ClinicalTrials.gov, NCT02151292. Findings Overall, 99 patients were randomised (65 to adavosertib–gemcitabine, 34 to placebo–gemcitabine). Progression-free survival was longer with adavosertib–gemcitabine (hazard ratio, 0·55; 95% confidence interval, 0·35–0·90; log-rank p=0·015; median 4·6 months with adavosertib–gemcitabine vs 3·0 months with placebo–gemcitabine). The most frequent grade ≥3 adverse events were haematological (neutropenia in 38/61 [62%] of adavosertib–gemcitabine-treated patients vs 10/33 [30%] of placebo–gemcitabine-treated patients; thrombocytopenia in 19/61 [31%] vs 2/33 [6%]). Homologous recombination deficiency, BRCA1/2 mutations, and CCNE1 amplification were associated with enhanced benefit from adavosertib but SLFN11 levels did not predict benefit from adavosertib–gemcitabine. Interpretation Adding adavosertib to gemcitabine significantly improved progression-free survival and overall survival in platinum-resistant/-refractory ovarian cancer. Combining gemcitabine with adavosertib increased toxicities, particularly haematological events. Patients with homologous repair gene mutations may benefit from adavosertib. Funding United States National Cancer Institute, US Department of Defense, Princess Margaret Cancer Foundation and AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Regulation of DNA repair throughout the cell cycle
Branzei, D., & Foiani, M. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2351 · Cited by 1,228
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
The control of DNA repair by the cell cycle
Hustedt, N., & Durocher, D. (2017) · Nature Cell Biology · doi:10.1038/ncb3452 · Cited by 738
SLFN11 inhibits checkpoint maintenance and homologous recombination repair
Mu, Y., Lou, J., Srivastava, M., Zhao, B., Feng, X., Liu, T., Chen, J., & Huang, J. (2016) · The EMBO Reports · doi:10.15252/embr.201540964 · Cited by 160
DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
Li, M., Kao, E., Malone, D., Gao, X., Wang, J. Y. J., & David, M. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0142-5 · Cited by 136
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
Self-citationShee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224267 · Cited by 43
Cited by
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Treatment Approaches for Platinum-Resistant Ovarian Cancer
St Laurent, J., & Liu, J. F. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01771 · Cited by 88
WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity
Elbæk, C. R., Petrosius, V., Benada, J., Erichsen, L., Damgaard, R. B., & Sørensen, C. S. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110261 · Cited by 64
Synthetic Lethality in Ovarian Cancer
Chandrasekaran, A., & Elias, K. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0500 · Cited by 41
Metadata
- Authors
- Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Wahner Hendrickson, A. E., Fleming, G. F., Welch, S., Dhani, N. C., Stockley, T., Rath, P., Karakasis, K., Jones, G. N., Jenkins, S., Rodriguez-Canales, J., Tracy, M., Tan, Q., Bowering, V., Udagani, S., Wang, L., Kunos, C. A., Chen, E., Pugh, T. J., & Oza, A. M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 397
- Issue
- 10271
- Pages
- 281-292
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3122624214
- Cited by
- 210
- References
- 8
- FWCI
- 27.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32554-x
- The paper
- Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Wahner Hendrickson, A. E., Fleming, G. F., Welch, S., Dhani, N. C., Stockley, T., Rath, P., Karakasis, K., Jones, G. N., Jenkins, S., Rodriguez-Canales, J., . . . Oza, A. M. (2021). Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)32554-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.